文章：

miRNA失调在多发性骨髓瘤发病机制中的作用

Roles of miRNA dysregulation in the pathogenesis of multiple myeloma 

原文发布日期：2021-01-05 

英文摘要：

Multiple myeloma (MM) is a malignant disease of plasma cells with complex pathology, causing significant morbidity due to its end-organ destruction. The outcomes of patients with myeloma have significantly improved in the past couple of decades with the introduction of novel agents, such as proteasome inhibitors, immunomodulators, and monoclonal antibodies. However, MM remains incurable and presents considerable individual heterogeneity. MicroRNAs (miRNAs) are short, endogenous noncoding RNAs of 19–22 nucleotides that regulate gene expression at the posttranscriptional level. Numerous studies have shown that miRNA deregulation is closely related to MM pathology, including tumor initiation, progression, metastasis, prognosis, and drug response, which make the complicated miRNA network an attractive and marvelous area of investigation for novel anti-MM therapeutic approaches. Herein, we mainly summarized the current knowledge on the roles of miRNAs, which are of great significance in regulating pathological factors involved in MM progressions, such as bone marrow microenvironment, methylation, immune regulation, genomic instability, and drug resistance. Meanwhile, their potential as novel prognostic biomarkers and therapeutic targets was also discussed. 

摘要翻译： 

多发性骨髓瘤（MM）是一种具有复杂病理学的浆细胞恶性疾病，因其终末器官破坏而导致显著发病率。过去二十年间，随着蛋白酶体抑制剂、免疫调节剂和单克隆抗体等新型药物的应用，骨髓瘤患者预后已显著改善。然而该疾病仍无法治愈，且存在显著的个体异质性。MicroRNA（miRNA）是一类长度为19-22个核苷酸的内源性非编码RNA，能在转录后水平调控基因表达。大量研究表明miRNA失调与MM病理过程密切相关，包括肿瘤发生、进展、转移、预后及药物反应，这使得复杂的miRNA网络成为开发新型抗MM疗法的热门研究领域。本文主要综述了当前关于miRNA在调控MM进展关键病理因素（如骨髓微环境、甲基化、免疫调节、基因组不稳定性及耐药性）中的重要作用，并探讨其作为新型预后生物标志物和治疗靶点的潜力。

原文链接：

Roles of miRNA dysregulation in the pathogenesis of multiple myeloma